Doctor of Optometry Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Aaron Lewis

Optometrist Enfield, CT Doctor of Optometry

NPI 1669090916 CMS profile 8002630

139 Hazard Ave Ste 1, Enfield, CT 06082

Open in the dashboard

General payments

$6,213

246 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Lewis of Enfield, CT is reported in the CMS Open Payments database as having received $6,213 across 246 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,517 56
2024 General $2,265 72
2023 General $962 44
2022 General $901 50
2021 General $532 22
2020 General $37 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Lewis
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Aaron Lewis were reported at $1,517. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Aaron Lewis Optometrist median Middle half National median
2019 $0 $159 $67–$371 $163
2020 $37 $72 $29–$165 $114
2021 $532 $125 $46–$292 $132
2022 $901 $162 $66–$374 $149
2023 $962 $177 $72–$406 $160
2024 $2,265 $188 $77–$427 $164
2025 $1,517 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Bausch & Lomb Americas Inc. $1,278 44 payments
  2. Alcon Vision LLC $1,002 43 payments
  3. Sun Pharmaceutical Industries Inc. $765 40 payments
  4. CooperVision Inc. $723 13 payments
  5. Novartis Pharmaceuticals Corporation $437 21 payments
  6. Tarsus Pharmaceuticals, Inc. $402 18 payments
  7. Johnson & Johnson Vision Care, Inc. $388 14 payments
  8. Dompe US, Inc. $274 14 payments
  9. Harrow Eye, LLC $216 13 payments
  10. Eyevance Pharmaceuticals LLC $197 5 payments
  11. Other $532 21 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $5,713 245 payments
  2. Consulting Fee $500 1 payment
Products named General payments · program years 2020–2025
  1. XIIDRA Ophthalmology $921 36 payments
  2. Cequa $765 40 payments
  3. MIEBO $712 22 payments
  4. MyDay Contact Lens $623 8 payments
  5. XDEMVY $402 18 payments
  6. INFUSE $378 13 payments
  7. OXERVATE $274 14 payments
  8. Acuvue $271 9 payments
  9. XIIDRA Ophthalmology $249 8 payments
  10. Precision7 $233 6 payments
  11. Other $2,192 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

135

Median for Optometry: 120

Drug cost

$84,833

Median for Optometry: $8,864

Branded share of claims

58.5%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 24 $35,294
Xiidra Lifitegrast Brand 15 $28,493
Miebo Perfluorohexyloctane/Pf Brand 16 $12,186
Tyrvaya Varenicline Tartrate Brand 12 $8,029
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 12 $436
Latanoprost Generic 27 $317
Timolol Maleate Generic 29 $78

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MIEBO
  • Bausch & Lomb Americas Inc. $212
$212 16 —
XIIDRA
  • Bausch & Lomb Americas Inc. $212
$212 15 —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $194
$194 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $182
$182 — —
VEVYE
  • Harrow Eye, LLC $155
$155 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

246 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record